Dental Surgery News
-
Practicing in the Digital Age: The Benefits of the SurgiCam HD
Summary The SurgiCam® HD, a specialized point-of-view camera designed for clinicians, plays a pivotal role in the documentation, education, and analysis of surgical, dental, and veterinary procedures. Its high-quality image and video capturing capabilities make it an indispensable tool in these fields. This innovative camera significantly enhances surgical practices, education, and research ...
-
The Use of Infrared Coagulation in Hair Transplant and Scalp Reduction Surgery
The infrared coagulator, a spin off of laser technology, has been used for more than a decade, first in Europe and then in the United States, for the in-office elimination offlrst and second degree hemorrhoids. Even more recently, it has been employed in the treatment and removal of unwanted tattoos. This device has been FDA approved for both anorectal and dermatologic applications. Within the ...
-
Lattice Medical announces the closing of a €8 million Series A financing round
LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt ...
-
A Guide to Dental Oral Surgeries
Oral surgeons have the skillset and the technology to transform their patients’ mouths. From relatively simple tasks like removing impacted teeth to life-saving measures like removing oral cancer, these highly skilled professionals are trained to rescue their patients in their time of need. There’s more than one way to get your teeth worked on. Dental surgeries come in many ...
-
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...
-
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a ...
-
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading ...
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...
-
Panama Increased Focus on Disposable Medical Supplies Long Before COVID-19
Prior to 2020 and the COVID-19 pandemic, the market for disposable medical supplies in Panama steadily grew at an average rate of 10% over the last decade, due to the growing population and increased public and private investment in the health sector. As a result of the pandemic, Panama has significantly increased spending on disposable medical supplies and is prepared to continue devoting ...
-
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
-
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 ...
-
enVVeno Medical Announces New U.S. VenoValve Patent
Expanding patent portfolio bolsters protection of the Company’s lead product The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in ...
-
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s ...
-
FDA clears Sonavex’s ultrasound blood flow monitor
Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand. The EchoSure system is cleared for use with the company’s EchoMark bioresorbable tissue markers, which got the agency’s nod in June. “The key goal is to be able to detect the problems associated with microvascular and vascular surgeries with ...
-
Checkpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical Study
Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology. The patient was enrolled at The Ohio State University, one of four sites actively enrolling patients in the double-blind, randomized clinical trial. Other ...
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
Agreement signed with TELA Bio Inc
Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc in relation to the supply of a white labelled version of Next Science’s proprietary XPERIENCETM No Rinse Antimicrobial Solution. The new agreement grants TELA Bio, Inc exclusive rights across the US plastic ...
-
CARMAT announces a new commercial implant of its Aeson artificial heart at University Medical Center Schleswig-Holstein in Kiel, Germany
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new commercial implant of the Aeson® device was ...
By Carmat
-
CARMAT announces the second center implanting its total artificial heart in the United States
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study. CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage ...
By Carmat
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you